Healx Logo

Michale Bouskila-Chubb recognised in 50 Movers and Shakers in BioBusiness Report

We’re delighted to announce that our Head of Business Development, Michale Bouskila-Chubb has been featured in the sixth annual Movers and Shakers in BioBusiness report which showcases the 50 trailblazers shaping the future of the UK life sciences sector.
5 November 2019   |  
X minutes
Featured image

Michale has been featured in recognition of her contribution to Healx’s business through the negotiation and closing of the company’s first pharma deals, navigating new issues such as data use and IP in drug discovery deals using artificial intelligence (AI).

In addition to this, Michale has been instrumental in developing Healx’s business activities through two investment rounds totalling $10 million (2018, Series A) and $56 million (2019, Series B).

The full 50 Movers and Shakers in BioBusiness 2019 report (available here) paints a picture of the UK as a vibrant hub for bioscience in creating life-changing advances.

The 50 women highlighted in this year’s report have been nominated by the biobusiness community for their work across the following categories: science, finance, collaboration, patient impact and infrastructure. The collaboration cohort that Michale is recognised in features an impressive roster of women – all united in their dedication to promoting collaborative working practices and forging strong relationships between people and organisations.

Miranda Weston-Smith, BioBeat founder:

“It’s a privilege to connect with these incredible leaders, discovering their work and hearing their thoughts on the direction of the industry. Their insights guide our thinking on the opportunities and challenges facing the UK life sciences sector, revealing how to harness the brightest and best ideas to make a difference for patients. These women are the ones to watch!”

Michale Bouskila-Chubb, Head of Business Development at Healx:

“Advances in AI and ML are set to transform the traditional pharma model. Biotech AI partnerships are taking off and it is this momentum that will drive the full impact of AI on the drug development process. I am deeply honoured to be included in this prestigious list. It is thanks to an exceptional team of pharmacologists, biocurators and tech experts that Healx creates meaningful and transformative collaborations with patient groups, biotech and pharma.”


About Michale Bouskila-Chubb

Michale joined Healx in 2017 and brings over 10 years of business experience in life sciences. After a research career across both academia and industry in the field of physiology and human metabolism, Michale completed an MBA specialising in Healthcare. From there, she went on to hold various commercial positions in management consultancy, technology transfer and pharmaceutical business development. Michale has a strong background in commercial strategy, IP exploitation and contract negotiations. She recently received the PLG (Pharmaceutical Licensing Group) Business Development Award for Best Newcomer of the year (2018).

Michale holds a Pharmacy doctorate and a Toxicology Master’s degree from Paris V University, a PhD from the University of Dundee and an MBA from the Open University Business School.

If you’re interested in learning more about Healx’s rare disease discovery and co-development partnership opportunities, please take a look at our partnerships page or get in touch with us.

You might also like: